Navigation Links
Nephrologists and Non-Nephrologists Alike Report Increased Attention on Chronic Kidney Disease

EXTON, Pa., May 23 /PRNewswire/ -- BioTrends Research Group, Inc. released a Special Report: "Referrals in Nephrology," providing insight into the referral patterns and co-management of patients with Chronic Kidney Disease (pre-dialysis) from the perspective of Nephrologists, Cardiologists, Endocrinologists, and Primary Care Physicians. The newly released syndicated report offers a comprehensive view, based on qualitative interviews with 40 physicians and quantitative feedback from close to 300 physicians, about awareness of CKD, triggers for referral, knowledge of and treatment with therapies for renal anemia, secondary hyperparathyroidism, hyperphosphatemia, and hypertension. It also includes 10 interviews with Managed Care Organizations to determine their involvement in referrals to Nephrologists and control mechanisms for various classes and brands of medications.

According to the study, awareness of CKD seems to be growing among all specialties. Although there is high agreement around the benefits of early screening for CKD, there is relatively low familiarity with the National Kidney Foundation's CKD Staging Classification and virtually no familiarity with the Kidney Early Evaluation Program (KEEP), a program designed to raise awareness, educate, provide physician referrals, and ultimately delay disease progression. While Endocrinologists and Cardiologists do refer patients with CKD to Nephrologists, the majority of referrals come from PCPs. Managed care does not play a role in when patients are referred to Nephrologists.

In terms of treatment of CKD patients, while all specialties are familiar with and comfortable prescribing ACEs and ARBs, there are differences between specialties when it comes to phosphate binders, PTH modifiers, ESAs, and IV Iron. Cardiologists are least interested in managing renal issues in patients with CKD. Some of the differences in level of involvement are specialty driven, whereas others seem to be based on practice setting (urban/rural/suburban) and practice type (solo/group/multi-specialty). Pharmaceutical companies appear to be taking different approaches to reaching these non-Nephrology physicians involved in the management of CKD patients. Some companies are targeting them directly while others are limiting promotion to Nephrologists.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. ( provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact Jennifer Robinson at (610) 363-3872 or

All company, brand, or product names contained in this document may be trademarks of their respective holders.

SOURCE BioTrends Research Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Awareness of Genzymes Renvela(R) (Sevelamer Carbonate) is High, Although Uptake of this New Phosphate Binding Agent has Been Slower than Nephrologists and Renal Dietitians Initially Expected
2. BioTrends Releases Two Publications - TreatmentTrends(TM): Nephrologists and TreatmentTrends(TM): Renal Dietitians - Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
3. Rosetta Genomics Reports First Quarter 2008 Financial Results
4. Genetic Engineering and Biotechnology News (GEN) Reports on Mass Spec in Drug Discovery
5. Advance Nanotech Reports First Quarter 2008 Financial Results
6. Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results
7. Senetek PLC Reports First Quarter 2008 Financial Results
8. New Study Reports That Ablative Therapy With HALO360 Device Effectively Treats Highest-Risk Category of Barretts Esophagus
9. China Biologic Products Reports First Quarter 2008 Results
10. Escalon(R) Reports Third Quarter Fiscal 2008 Results
11. Cadus Reports First Quarter 2008 Results
Post Your Comments:
(Date:6/23/2016)... 2016 A person commits a crime, and the ... track the criminal down. An outbreak of foodborne ... Administration (FDA) uses DNA evidence to track down the bacteria ... far-fetched? It,s not. The FDA has increasingly used a complex, ... foodborne illnesses. Put as simply as possible, whole genome sequencing ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network ... Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is ... projects are designed, built and brought to market. , The Design Lab is ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
Breaking Biology Technology:
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/26/2016)... April 27, 2016 Research ... Multi-modal Biometrics Market 2016-2020"  report to their offering.  ... The analysts forecast the global multimodal ... 15.49% during the period 2016-2020.  Multimodal ... sectors such as the healthcare, BFSI, transportation, automotive, ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):